These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 9045946)

  • 1. Production of murine leukemia RLmale1 rejection antigen peptide pRL1a by proteolysis of natural precursor pRL1b.
    Ono T; Uenaka A; Nakayama E
    Jpn J Cancer Res; 1996 Nov; 87(11):1165-70. PubMed ID: 9045946
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Expression of multiple unique rejection antigens on murine leukemia BALB/c RLmale symbol1 and the role of dominant Akt antigen for tumor escape.
    Matsuo M; Wada H; Honda S; Tawara I; Uenaka A; Kanematsu T; Nakayama E
    J Immunol; 1999 Jun; 162(11):6420-5. PubMed ID: 10352255
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Vaccination with multiple antigen peptide as rejection antigen peptide in murine leukemia.
    Manki A; Ono T; Uenaka A; Seino Y; Nakayama E
    Cancer Res; 1998 May; 58(9):1960-4. PubMed ID: 9581839
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Diversity of epitopes recognized by cytotoxic T lymphocytes that are specific for rejection antigen peptide pRL1a presented on BALB/c leukemia RL Male 1.
    Yokoi T; Uenaka A; Ono T; Onizuka S; Inoue H; Nakayama E
    Int Immunol; 1997 Aug; 9(8):1195-201. PubMed ID: 9263017
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Analysis of CD8 T-cell response by IFNgamma ELISPOT and H-2L(d)/pRL1a tetramer assays in pRL1a multiple antigen peptide-immunized and RL male 1-bearing BALB/c and (BALB/c x C57BL/6) F(1) mice.
    Takada I; Noguchi Y; Kenjo A; Wada H; Uenaka A; Fujita T; Inoue H; Nakayama E
    Cancer Sci; 2004 Mar; 95(3):254-9. PubMed ID: 15016326
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Identification of a unique antigen peptide pRL1 on BALB/c RL male 1 leukemia recognized by cytotoxic T lymphocytes and its relation to the Akt oncogene.
    Uenaka A; Ono T; Akisawa T; Wada H; Yasuda T; Nakayama E
    J Exp Med; 1994 Nov; 180(5):1599-607. PubMed ID: 7964448
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cellular processing of a multibranched lysine core with tumor antigen peptides and presentation of peptide epitopes recognized by cytotoxic T lymphocytes on antigen-presenting cells.
    Ota S; Ono T; Morita A; Uenaka A; Harada M; Nakayama E
    Cancer Res; 2002 Mar; 62(5):1471-6. PubMed ID: 11888922
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Double-cleavage production of the CTL epitope by proteasomes and PA28: role of the flanking region.
    Shimbara N; Nakajima H; Tanahashi N; Ogawa K; Niwa S; Uenaka A; Nakayama E; Tanaka K
    Genes Cells; 1997 Dec; 2(12):785-800. PubMed ID: 9544705
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Occurrence of tumor antigen pRL1a specific CD8 T cells in spleen cells from syngeneic BALB/c, semiallogeneic (BALB/c x C57BL/6)F1 and allogeneic C57BL/6 mice.
    Hata H; Uenaka A; Takada I; Kenjo A; Takahashi M; Ono T; Fujita T; Nakayama E
    Int J Oncol; 2002 May; 20(5):1019-25. PubMed ID: 11956599
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Possible involvement of autoreactive CD4 T cells in generation of cytotoxic T lymphocytes on in vitro stimulation with H-2 class I-binding tumor antigen peptide.
    Honda S; Wada H; Uenaka A; Nakayama E
    Int Immunol; 1998 Aug; 10(8):1167-74. PubMed ID: 9723703
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Identification of a CD4 T-cell epitope in tumor rejection antigen RLakt on BALB/c radiation-leukemia RL male 1.
    Kaya S; Uenaka A; Sato S; Ono T; Aji T; Nakayama E
    Cancer Sci; 2008 Jul; 99(7):1441-7. PubMed ID: 18452555
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Murine leukemia RL male 1 and sarcoma Meth A antigens recognized by cytotoxic T lymphocytes (CTL).
    Uenaka A; Nakayama E
    Cancer Sci; 2003 Nov; 94(11):931-6. PubMed ID: 14611667
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A novel type of prolactin expressed in the bullfrog pituitary specifically during the larval period.
    Okada R; Suzuki M; Ito N; Hyodo S; Kikuyama S
    Gen Comp Endocrinol; 2019 May; 276():77-85. PubMed ID: 30735673
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cell surface antigens of radiation leukemia virus-induced BALB/c leukemias defined by syngeneic cytotoxic T lymphocytes.
    Kaneko Y; Oettgen HF; Obata Y; Nakayama E
    Jpn J Cancer Res; 1989 Mar; 80(3):257-64. PubMed ID: 2542207
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Localization of two cytotoxic T lymphocyte epitopes and three anchoring residues on a single nonameric peptide that binds to H-2Ld and is recognized by cytotoxic T lymphocytes against mouse tumor P815.
    Van den Eynde B; Mazarguil H; Lethé B; Laval F; Gairin JE
    Eur J Immunol; 1994 Nov; 24(11):2740-5. PubMed ID: 7525302
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cell surface antigens of murine leukemias induced by radiation leukemia virus. Recognition of individually distinct cell surface antigens by cytotoxic T cells on leukemias expressing crossreactive transplantation antigens.
    Morishita H; Shiku H; Horibe K; Obata Y; Stockert E; Oettgen HF; Old LJ; Yamada K
    J Exp Med; 1986 Feb; 163(2):452-7. PubMed ID: 3003228
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Identification of Meth A sarcoma-derived class I major histocompatibility complex-associated peptides recognized by a specific CD8+ cytotoxic T lymphocyte.
    Frassanito MA; Mayordomo JI; DeLeo RM; Storkus WJ; Lotze MT; DeLeo AB
    Cancer Res; 1995 Jan; 55(1):124-8. PubMed ID: 7528638
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rejection antigen peptides on BALB/c RL male 1 leukemia recognized by cytotoxic T lymphocytes: derivation from the normally untranslated 5' region of the c-akt proto-oncogene activated by long terminal repeat.
    Wada H; Matsuo M; Uenaka A; Shimbara N; Shimizu K; Nakayama E
    Cancer Res; 1995 Nov; 55(21):4780-3. PubMed ID: 7585504
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Identification and quantification of a naturally presented peptide as recognized by cytotoxic T lymphocytes specific for an immunogenic tumor variant.
    Wallny HJ; Deres K; Faath S; Jung G; Van Pel A; Boon T; Rammensee HG
    Int Immunol; 1992 Oct; 4(10):1085-90. PubMed ID: 1283332
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Recurrent T cell receptor rearrangements in the cytotoxic T lymphocyte response in vivo against the p815 murine tumor.
    Levraud JP; Pannetier C; Langlade-Demoyen P; Brichard V; Kourilsky P
    J Exp Med; 1996 Feb; 183(2):439-49. PubMed ID: 8627157
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.